{"product_id":"jubilantpharmova-pestle-analysis","title":"Jubilant Pharmova PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUncover how political shifts, economic trends, and regulatory pressures are shaping Jubilant Pharmova’s strategic outlook with our concise PESTLE snapshot. This three-to-five sentence overview highlights key external drivers and risks. For the full, actionable PESTLE—ready for investors and strategists—purchase the complete report and download instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment reimbursement and procurement priorities shape demand for radiopharmaceuticals and injectables, with the global radiopharmaceuticals market valued at about USD 6.7 billion in 2023 and a ~7.5% CAGR projected to 2030. Changes in national formularies, nuclear medicine funding and allergy program coverage can shift product mix toward high-margin radiopharma or allergy injectables. Stable health budgets support CDMO pipeline visibility by enabling multi-year contracts and capacity planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics and trade\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExport controls, tariffs and sanctions since 2022, notably those affecting Russia and Ukraine, have disrupted isotope sourcing and global routes for radiopharmaceutical precursors, forcing companies like Jubilant Pharmova to reroute supplies and absorb higher freight and compliance costs.\u003c\/p\u003e\n\u003cp\u003eCross-border movement of sterile injectables and APIs hinges on bilateral regulatory recognition and GMP equivalence; delays in mutual recognition extend batch clearance times, increasing holding periods and cold-chain costs.\u003c\/p\u003e\n\u003cp\u003ePolitical tensions and trade restrictions have lengthened lead times by weeks to months in recent years, raising working capital needs through larger safety inventories and higher pre-shipment financing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic procurement rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic procurement tender dynamics in hospitals set aggressive price benchmarks and 1–3 year contract durations, directly influencing Jubilant Pharmova’s bidding strategy and pricing power.\u003c\/p\u003e\n\u003cp\u003ePreference policies and local content requirements in India and export markets steer site footprint decisions and partnerships toward domestic manufacturing and contract manufacturing organizations.\u003c\/p\u003e\n\u003cp\u003eMulti-year framework agreements provide volume stability but typically compress margins into low single-digit percentage points, pressuring EBITDA unless offset by scale or cost actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNuclear material governance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicenses for handling and transporting radioisotopes remain politically sensitive for Jubilant Pharmova, requiring national permits and customs clearances that can delay shipments and increase compliance costs. Policy shifts in nuclear infrastructure investment directly affect medical isotope availability and supply-chain resilience. International treaties such as the NPT (191 parties) and IAEA safety\/security standards impose operational constraints and reporting obligations on radiopharma operations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing risk: increased regulatory scrutiny and customs delays\u003c\/li\u003e\n\u003cli\u003eSupply impact: national nuclear investment alters isotope access\u003c\/li\u003e\n\u003cli\u003eCompliance: NPT\/IAEA standards mandate reporting and safety measures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncentives and clusters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment incentives such as India’s 6,940 crore production-linked incentive for bulk drugs shape Jubilant Pharmova’s capex location decisions by improving project IRR and lowering payback periods; life-science cluster policies in hubs like Bengaluru and Hyderabad ease access to skilled talent and CRO\/CDMO partners; grants and tax credits materially tilt returns on sterile capacity expansions by reducing effective capital cost.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePLI outlay: 6,940 crore (bulk drugs)\u003c\/li\u003e\n\u003cli\u003eCluster benefit: faster hiring, shared CRO\/CDMO access\u003c\/li\u003e\n\u003cli\u003eSterile capex: grants\/tax credits improve ROI and shorten payback\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement, PLI and isotope rules reshape radiopharma sites, capex and bids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment procurement, PLI incentives and local content rules shape site, capex and bidding choices, with the global radiopharmaceuticals market at ~USD 6.7bn (2023) and ~7.5% CAGR to 2030. Trade restrictions, export controls and isotope licensing (NPT 191 parties; IAEA standards) raise lead times, cold‑chain and compliance costs. Public tenders (1–3yr) and multi‑year frameworks drive volume but compress margins to low single digits.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiopharma market (2023)\u003c\/td\u003e\n\u003ctd\u003eUSD 6.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected CAGR\u003c\/td\u003e\n\u003ctd\u003e~7.5% to 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLI (bulk drugs)\u003c\/td\u003e\n\u003ctd\u003e6,940 crore INR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPT parties\u003c\/td\u003e\n\u003ctd\u003e191\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract length\u003c\/td\u003e\n\u003ctd\u003e1–3 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin impact\u003c\/td\u003e\n\u003ctd\u003eLow single digits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental and Legal factors specifically impact Jubilant Pharmova, combining data-backed trends and forward-looking insights to help executives, investors and strategists identify risks, opportunities and inform scenario-based planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of Jubilant Pharmova that distills regulatory, market and macro risks for quick reference, editable for local context and easily dropped into presentations or shared across teams to streamline strategy discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency and inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMulti-currency revenues versus predominantly INR cost bases expose Jubilant Pharmova to USD\/INR and EUR\/INR swings, pressuring reported margins when the rupee weakens. Inflation in energy, labor and vial\/syringe inputs—with India headline CPI around 5% in 2024 and RBI anchor at 4%—adds cost pressure. The company uses hedging and index-linked pricing in contracts to partially mitigate FX and input-price volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal demand cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising chronic disease burden sustains radiopharma demand, with noncommunicable diseases causing about 41 million deaths annually (74% of global deaths) per WHO 2024, supporting growth in diagnostic imaging and nuclear medicine services.\u003c\/p\u003e\n\u003cp\u003eBiotech funding cycles remain volatile and directly affect CDMO order books, with deal flow and milestone payments driving capacity utilization swings in 2023–24.\u003c\/p\u003e\n\u003cp\u003eHospital budget tightening is delaying product switches and new therapy uptake, lengthening procurement cycles and pressuring pricing for radiopharma and CDMO services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExternal reference pricing and HTA decisions, notably NICE thresholds of around 20,000–30,000 pounds per QALY, constrain price upside in the UK and EU while HTA is institutionalized in over 50 countries. Pooled\/bundled procurement strategies force volume-for-price tradeoffs in public tenders. Robust value dossiers supported by real-world evidence — endorsed under FDA's RWE framework and EU initiatives — are becoming key economic differentiators for Jubilant Pharmova.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCold-chain logistics and just-in-time isotopes raise Jubilant Pharmova's distribution costs, with cold-chain premiums typically 10–20% higher and JIT transport increasing per-shipment expenses; freight volatility and lane constraints (airfreight swings \u0026gt;30% in recent cycles) erode service levels and increase expedited shipments; dual sourcing and nearshoring strengthen resilience but add fixed CAPEX and operating costs, often near 10% uplift.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ecold-chain premium: 10–20%\u003c\/li\u003e\n\u003cli\u003eairfreight volatility: \u0026gt;30% swings\u003c\/li\u003e\n\u003cli\u003eresilience cost uplift: ~10% fixed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSterile fill-finish and radiopharma facilities demand heavy capex—typically $50–150m per sterile line and $100m+ for radiopharmaceutical plants—raising fixed-cost intensity for Jubilant Pharmova. Elevated interest rates (India repo ~6.5% in mid‑2025) push WACC and project hurdle rates higher, compressing NPV on greenfield builds. Maintaining \u0026gt;80% utilization is essential to cover fixed charges and defend IRR targets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapex range: $50–150m per sterile line\u003c\/li\u003e\n\u003cli\u003eRadiopharma build: $100m+\u003c\/li\u003e\n\u003cli\u003eRepo\/WACC signal: repo ~6.5% (mid‑2025)\u003c\/li\u003e\n\u003cli\u003eTarget utilization: \u0026gt;80% to protect returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement, PLI and isotope rules reshape radiopharma sites, capex and bids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJubilant faces FX exposure with ~65% revenues in USD\/EUR vs INR costs; CPI ≈5% (2024) and repo ≈6.5% (mid‑2025) raise input and finance costs. Sterile lines cost $50–150m; radiopharma \u0026gt;$100m, requiring \u0026gt;80% utilization to protect margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX mix\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI (2024)\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepo (mid‑2025)\u003c\/td\u003e\n\u003ctd\u003e~6.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterile capex\u003c\/td\u003e\n\u003ctd\u003e$50–150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiopharma capex\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUtilization target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eJubilant Pharmova PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Jubilant Pharmova PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use. This document contains the same content, layout and structure visible now, with no placeholders or surprises. After payment you’ll instantly download this final, professionally prepared file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162796732793,"sku":"jubilantpharmova-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/jubilantpharmova-pestle-analysis.png?v=1762708894","url":"https:\/\/portersfiveforce.com\/products\/jubilantpharmova-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}